LPKF moves ARRALYZE into BioLabs Boston
EQS-Media / 12.07.2023 / 11:12 CET/CEST
Garbsen, July 12, 2023 -The technology company LPKF Laser Electronics SE and its new biotechnology division ARRALYZE will move into the BioLabs Group's renowned co-working spaces in Boston, USA, this July. BioLabs helps startups bring breakthrough new ideas and technologies to Life-Science markets. In doing so, BioLabs selects only innovations that have the potential to advance the life sciences and make a tangible contribution to improving medical care. For this, Tufts Launchpad | BioLabs was awarded the 2022 Prix Galien USA Award. (www.prnewswire.com/news-releases/biolabs-and-labcentral-win-2022-prix-galien-usa-award-301664861.html)
LPKF has been developing systems and solutions for biomedical applications under the name ARRALYZE for two years. The systems work with glass arrays manufactured with LPKF's proprietary LIDE technology. ARRALYZE offers a complete solution for scalable single cell screening in biomedical research and is one of LPKF's strategic growth initiatives. With its inclusion in BioLabs Boston, ARRALYZE is right at the center of the world's most important biotech network. Hardware and application development for ARRALYZE takes place at LPKF's headquarters in Garbsen near Hanover.
For LPKF's CEO Klaus Fiedler, the new lab in Boston is both an award and a stepping stone for ARRALYZE. "The biotech industry is developing rapidly and the United States, especially Boston, has become a center for innovation and scientific progress. Having a presence in Boston gives us the global reach that we need. In addition, the collaboration, networking and knowledge sharing with other startups and industry experts is invaluable to our team."
About LPKF
LPKF Laser Electronics SE is a leading provider of laser-based solutions for the technology industry. Laser systems from LPKF are crucial for the production of printed circuit boards, microchips, automotive parts, solar modules and many other components. Founded in 1976, the company is headquartered in Garbsen near Hanover, Germany, and is active worldwide through subsidiaries and representatives. LPKF Laser Electronics SE shares are traded in the Prime Standard segment of Deutsche Börse (ISIN 0006450000).
Contact:
Daniel Tolle, Head of Investor Relations Treasury
LPKF has been developing systems and solutions for biomedical applications under the name ARRALYZE for two years. The systems work with glass arrays manufactured with LPKF's proprietary LIDE technology. ARRALYZE offers a complete solution for scalable single cell screening in biomedical research and is one of LPKF's strategic growth initiatives. With its inclusion in BioLabs Boston, ARRALYZE is right at the center of the world's most important biotech network. Hardware and application development for ARRALYZE takes place at LPKF's headquarters in Garbsen near Hanover.
For LPKF's CEO Klaus Fiedler, the new lab in Boston is both an award and a stepping stone for ARRALYZE. "The biotech industry is developing rapidly and the United States, especially Boston, has become a center for innovation and scientific progress. Having a presence in Boston gives us the global reach that we need. In addition, the collaboration, networking and knowledge sharing with other startups and industry experts is invaluable to our team."
Under the name ARRALYZE, LPKF develops systems and solutions for biomedical applications.
About LPKF
LPKF Laser Electronics SE is a leading provider of laser-based solutions for the technology industry. Laser systems from LPKF are crucial for the production of printed circuit boards, microchips, automotive parts, solar modules and many other components. Founded in 1976, the company is headquartered in Garbsen near Hanover, Germany, and is active worldwide through subsidiaries and representatives. LPKF Laser Electronics SE shares are traded in the Prime Standard segment of Deutsche Börse (ISIN 0006450000).
Contact:
Daniel Tolle, Head of Investor Relations Treasury
End of Media Release
Issuer: LPKF Laser Electronics SE
Key word(s): Research/Technology
12.07.2023 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
End of News EQS Media
1678495 12.07.2023 CET/CEST